Principal Investigator
Carl Landgren
Enrollment Status
Not Accepting
Clinical Trial ID
Institutional Protocol #
20220203
Clinical Trial Summary
First-in-Human Study of the BCL-2 Inhibitor ABBV-453 in Biomarker-Selected Subjects with Relapsed or Refractory Multiple Myeloma
Phase
Phase I
Funding Agency/Sponsor
Industrial
Disease
Myeloma
Contact Information
Phone Number
305-243-2647